Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma
Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody-drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immuno...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
BioExcel Publishing Ltd,
2021-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1e2a1d4958ab4bd3ac57a831490d40e7 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Omar Castaneda-Puglianini |e author |
| 700 | 1 | 0 | |a Julio C Chavez |e author |
| 245 | 0 | 0 | |a Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma |
| 260 | |b BioExcel Publishing Ltd, |c 2021-09-01T00:00:00Z. | ||
| 500 | |a 10.7573/dic.2021-2-4 | ||
| 500 | |a 1740-4398 | ||
| 520 | |a Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody-drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity in poor-risk B cell NHL and MM. Several constructs are currently available and in clinical development for the treatment of these malignancies. Here, we present a narrative review of the most current data on bispecific antibodies in B cell NHL and MM. | ||
| 546 | |a EN | ||
| 690 | |a bispecific | ||
| 690 | |a immunotherapy | ||
| 690 | |a multiple myeloma | ||
| 690 | |a non-hodgkin's lymphoma | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drugs in Context, Vol 10, Pp 1-12 (2021) | |
| 787 | 0 | |n https://www.drugsincontext.com/bispecific-antibodies-for-non-hodgkins-lymphomas-and-multiple-myeloma | |
| 787 | 0 | |n https://doaj.org/toc/1740-4398 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1e2a1d4958ab4bd3ac57a831490d40e7 |z Connect to this object online. |